Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.56 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... 
Via Benzinga
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
Why Pfizer Stock Is Moving Higher on Thursday
Pfizer announced it will advance development of its once-daily Danuglipron. 
Via Benzinga
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE: PFE) is showing a bullish Golden Cross, indicating potential upward momentum for the stock. 
Via Benzinga
Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said he is staying long on Pfizer Inc. 
Via Benzinga
7 Hated Stocks Set to Make a Major Comeback This Year
These seven out-of-favor stocks across various sectors have the potential to stage a significant rebound as market conditions improve. 
Via InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. 
Via InvestorPlace
Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
Despite their recent underperformance, these two phenomenal dividend stocks -- sporting an average yield of 5.79% -- have the recipes to make their patient shareholders notably richer. 
Via The Motley Fool
Current Analysis: Pfizer Inc.
Pfizer (PFE​​​​​​​) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer’s share price rose about 20.5% from $36.32 to $30.02 as of... 
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On... 
Via Benzinga
3 Under $50 Stocks to Buy Now: Q3 Edition
For small do-it-yourself investors looking for value, the following under $50 stocks are worth buying in July 2024. 
Via InvestorPlace
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years. 
Via The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
2 Pharma Stocks to Buy Hand Over Fist This Month
These drugmakers may not be in perfect health right now, but that shouldn't last much longer. 
Via The Motley Fool
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector underperforms. 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate... 
Via Benzinga
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Wall Street Weighs In As Pfizer Targets $100 Billion Weight Loss Market
Pfizer announced plans to advance a once-daily version of its weight loss pill, danuglipron, following encouraging early-stage trial results. 
Via Talk Markets
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Phase 1 pharmacokinetic study results. Dose optimization studies will follow... 
Via Benzinga
Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug
The company now plans to run multiple tests of the drug, danuglipron, to determine the right dose for registration-enabling studies. 
Via Investor's Business Daily
Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone
Several stocks angled higher early Thursday with one in a buy zone and two looking to reclaim key levels. 
Via Investor's Business Daily
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.